Press Releases

Date Title and Summary View
May 30, 2019
MacroGenics to Participate in Jefferies Healthcare Conference
Rockville, MD , May 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
May 28, 2019
MacroGenics to Host Conference Call and Webcast to Review Margetuximab Phase 3 SOPHIA Study Presentation at ASCO
Rockville, MD , May 28, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced it will host a conference call and audio
May 15, 2019
MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
Study meets first sequential primary endpoint of progression-free survival (PFS) in head-to-head with current standard of care (trastuzumab and chemotherapy) Oral abstract will be presented at American Society of Clinical Oncology ( ASCO ) Annual Meeting on June 4, 2019 at 9:45 a.m.
May 01, 2019
MacroGenics Provides Update on Corporate Progress and First Quarter 2019 Financial Results
Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md. , May 01, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer,
Apr 24, 2019
MacroGenics Announces Date of First Quarter 2019 Financial Results Conference Call
ROCKVILLE, MD , April 24, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its
Apr 03, 2019
MacroGenics Reports Presentation of Data at the AACR Annual Meeting 2019
ROCKVILLE, MD , April 03, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the presentation of preclinical and
Apr 02, 2019
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , April 02, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Mar 08, 2019
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , March 08, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Feb 26, 2019
MacroGenics Provides Update on Corporate Progress and 2018 Financial Results
Margetuximab: Positive Phase 3 SOPHIA study with BLA submission planned for second half of 2019; Plans to initiate Phase 2/3 registration-directed, front-line gastric cancer study Enoblituzumab: Encouraging anti-PD-1 combo data supports Phase 2 study initiation in second half of 2019 PD-1
Feb 25, 2019
MacroGenics Announces Participation in SVB Leerink Global Healthcare Conference
ROCKVILLE, MD , Feb. 25, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Feb 19, 2019
MacroGenics Announces Date of Fourth Quarter and Full Year 2018 Financial Results Conference Call
ROCKVILLE, MD , Feb. 19, 2019 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that on Tuesday, February 26, 2019 ,
Feb 13, 2019
MacroGenics to Participate in Guggenheim Healthcare Talks Idea Forum
ROCKVILLE, MD , Feb. 13, 2019 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Feb 12, 2019
MacroGenics Announces Pricing of Public Offering of Common Stock
ROCKVILLE, MD , Feb. 12, 2019 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the pricing of an underwritten public
Feb 12, 2019
MacroGenics Announces Proposed Public Offering of Common Stock
ROCKVILLE, MD , Feb. 12, 2019 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has commenced an underwritten
Feb 06, 2019
MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab
Margetuximab improved progression-free survival (PFS) compared to HERCEPTIN® (trastuzumab), when used in combination with chemotherapy in patients with HER2+ metastatic breast cancer BLA submission targeted for second half of 2019 Company to host conference call today at 8:30 AM (ET) ROCKVILLE, MD
Jan 25, 2019
MacroGenics Announces Removal of Partial Clinical Hold on MGD009 Program by FDA
ROCKVILLE, MD , Jan. 25, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the U.S.
Jan 17, 2019
Updated Clinical Data from Combination of Margetuximab and Pembrolizumab in Gastric Cancer Presented at 2019 ASCO Gastrointestinal Cancers Symposium
32.7% Objective response rate in HER2+ IHC 3+ second-line gastric cancer patients Well tolerated in dose escalation and expansion cohorts ROCKVILLE, MD , Jan. 17, 2019 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and
Jan 07, 2019
MacroGenics to Present at the 37th Annual J.P. Morgan Healthcare Conference
Rockville, MD , Jan. 07, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig , M.D., Ph.D.,
Dec 07, 2018
MacroGenics Announces Partial Clinical Hold on MGD009 Phase 1 Studies
ROCKVILLE, MD , Dec. 07, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that on December 6 , it received a
Dec 03, 2018
Phase 1 Expansion Cohort Oral Presentations for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, in Relapsed/Refractory Acute Myeloid Leukemia Presented at 60th ASH Annual Meeting
Flotetuzumab demonstrated 29.4% complete response rate in evaluable primary refractory AML patients Translational studies suggest potential strategy for biomarker-based patient selection ROCKVILLE, Md. , Dec. 03, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc.
Nov 29, 2018
MacroGenics and Zai Lab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Margetuximab, MGD013 and TRIDENT™ Molecule in Greater China
Comprehensive collaboration across three MacroGenics’ pipeline programs to accelerate and expand ongoing development Expand Zai Lab’s late-stage clinical pipeline with margetuximab and obtain rights to first-in-class dual checkpoint inhibitor, MGD013 Jointly conduct global studies across multiple
Nov 27, 2018
MacroGenics Announces Participation in Three Investor Conferences
ROCKVILLE, MD , Nov. 27, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Nov 14, 2018
MacroGenics Announces Poster Presentation on Preclinical PD-L1 x CD137 DART® Program at the EORTC-NCI-AACR Symposium in Dublin
ROCKVILLE, MD , Nov. 14, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it had presented a poster titled
Nov 09, 2018
MacroGenics Reports Presentation of Clinical Data at 33rd Annual SITC Meeting
Enoblituzumab + pembrolizumab combination study data reported: ORRs in anti-PD-1/PD-L1 naïve SCCHN and NSCLC cohorts benchmarked favorably vs. approved anti-PD-1 agents Interim data from Phase 1 dose expansion study of MGA012 (anti-PD-1): objective responses in NSCLC, cervical cancer, endometrial
Nov 07, 2018
MacroGenics Provides Update on Corporate Progress and 3rd Quarter 2018 Financial Results
Margetuximab: Phase 3 SOPHIA study enrollment completed; topline results 1Q 2019 PD-1 franchise: MGD013 cohort expansions initiated; $15 million in MGA012 milestones triggered; MGD019 IND cleared B7-H3 franchise: enoblituzumab oral presentation at SITC ; MGC018 Phase 1 study initiating